Defects of mitochondrial electron transport chain in bipolar disorder: Implications for mood-stabilizing treatment

Canadian Journal of Psychiatry

Volumn 52, Issue 12, 2007, Pages 753-762

  Wang, Jun Feng ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bipolar disorder; Mitochondrial electron transport chain; Mood stabilizing drugs; Neuroprotection; Oxidative damage; Reactive oxygen species

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; REACTIVE OXYGEN METABOLITE; VALPROIC ACID;

ANTIOXIDANT ACTIVITY; ANXIETY; BIPOLAR DISORDER; CELL DAMAGE; COMPLEX FORMATION; GENE DELETION; GENE MUTATION; HAIR LOSS; HUMAN; LIBIDO; MITOCHONDRIAL ENERGY TRANSFER; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NONHUMAN; REVIEW; SIDE EFFECT; TREMOR; WEIGHT GAIN; XEROSTOMIA;

EID: 37749029999     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370705201202     Document Type: Review

References (109)

1. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003;17:491-511.
2. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167-181.
3. Stimmel GL. Economic grand rounds: the economic burden of bipolar disorder. Psychiatr Serv. 2004;55:117-118.
4. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry. 2000;61(Supp 13):38-41.
5. Soares JC, Mann JJ. The anatomy of mood disorders eview of structural neuroimaging studies. Biol Psychiatry. 1997;41:86-106.
6. Drevets WC, Ongur D, Price JL. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry. 1998;3:220-226, 190-191.
7. Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. Biol Psychiatry. 2000;48:486-504.
8. Drevets WC, Price JL, Simpson JR, et al. Subgenal prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824-827.
9. Rajkowska G. Morphometric methods for studying the prefrontal cortex in suicide victims and psychiatric patients. Ann N Y Acad Sci. 1997;836:253-268.
10. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. J Psychiatr Res. 1997;31:393-432.
11. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry. 2001;49:741-752.
12. Benes FM, Kwok EW, Vincent SL, et al. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry. 1998;44:88-97.
13. Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry. 2001;50:395-406.
14. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998;95:13290-13295.
15. Bezchlibnyk YB, Sun X, Wang JF, et al. Neuron somal size is decreased in the lateral amygdalar subnucleus from subjects with bipolar disorder. J Psychiatry Neurosci. 2007;32:203-210.
16. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal. 2005;7:1140-1149.
17. Genova ML, Bianchi C, Lenaz G. Structural organization of the mitochondrial respiratory chain. Ital J Biochem. 2003;52:58-61.
18. Schagger H. Respiratory chain supercomplexes. IUBMB Life. 2001;52:119-128.
19. Moro MA, Almeida A, Bolanos JP, et al. Mitochondrial respiratory chain and free radical generation in stroke. Free Radic Biol Med. 2005 15;39:1291-1304.
20. Stadtman ER. Protein oxidation and aging. Science. 1992;257:1220-1224.
21. Imlay JA, Linn S. DNA damage and oxygen radical toxicity. Science. 1988;240;1302-1309.
22. Skaper SD, Floreani M, Ceccon M, et al. Excitotoxicity, oxidative stress, and the neuroprotective potential of melatonin. Ann NY Acad Sci. 1999;890:107-118.
23. Youdim MB, Lavie L, Riederer P. Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide. Ann NY Acad Sci. 1994;738:64-68.
24. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol. 1998;44:110-114.
25. Shimohama S. Apoptosis in Alzheimer's disease-an update. Apoptosis. 2000;5:9-16.
26. Multhaup G, Ruppert T, Schlicksupp A, et al. Reactive oxygen species and Alzheimer disease. Biochem Pharmacol. 1997;54:533-539.
27. Datta K, Sinha S, Chattopadhyay P. Reactive oxygen species in health and disease. Natl Med J India. 2000;13:304-310.
28. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15:287-310.
29. Grima G, Benz B, Parpura V, et al. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res. 2003;62:213-224.
30. Chinopoulos C, Adam-Vizi V. Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J. 2006;273:433-450.
31. Gunter TE, Yule DI, Gunter KK, et al. Calcium and mitochondria. FEBS Lett. 2004;567:96-102.
32. Gogvadze V, Orrenius S, Zhivotovsky B. Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta. 2006;1757:639-647.
33. Kato T, Takahashi S, Shioiri T, et al. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord. 1992;26:223-230.
34. Kato T, Takahashi S, Shioiri T, et al. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord. 1994;31:125-133.
35. Kato T, Shioiri T, Murashita J, et al. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS. Psychol Med. 1995;25:557-566.
36. Hamakawa H, Kato T, Shioiri T, et al. Quantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder. Psychol Med. 1999;29:639-644.
37. Deicken RF, Fein G, Weiner MW. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am J Psychiatry. 1995;152:915-918.
38. Volz HP, Rzanny R, Riehemann S, et al. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci. 1998;248:289-295.
39. Moore CM, Christensen JD, Lafer B, et al. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry. 1997;154:116-118.
40. Kato T, Takahashi S, Shioiri T, et al. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J Affect Disord. 1993;27:53-59.
41. Hamakawa H, Murashita J, Yamada N, et al. Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin Neurosci. 2004;58:82-88.
42. Kato T, Murashita J, Kamiya A, et al. Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur Arch Psychiatry Clin Neurosci. 1998;248:301-306.
43. Sun X, Wang JF, Tseng M, et al. Down regulation in components of mitochondrial electron transport chain in post-mortem frontal cortex from subjects with bipolar disorder. J Psychiatry Neurosci. 2006;31:189-196.
44. Dager SR, Friedman SD, Parow A, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61:450-458.
45. Purdon AD, Rapoport SI. Energy requirements for two aspects of phospholipid metabolism in mammalian brain. Biochem J. 1998;335:313-318.
46. Deicken RF, Weiner MW, Fein G. Decreased temporal lobe phosphomonoesters in bipolar disorder. J Affect Disord. 1995;33:195-199.
47. Moore GJ, Galloway MP. Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders. Psychopharmacol Bull. 2002;36:5-23.
48. Hamakawa H, Kato T, Murashita J, et al. Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci. 1998;248:53-58.
49. Davanzo P, Yue K, Thomas MA, et al. Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry. 2003;160:1442-1452.
50. Sharma R, Venkatasubramanian PN, Barany M, et al. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res. 1992;8:43-49.
51. Yildiz A, Sachs GS, Dorer DJ, et al. 31P nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis. Psychiatry Res. 2001;106:181-191.
52. Hahn CG, Gomez G, Restrepo D, et al. Aberrant intracellular calcium signaling in olfactory neurons from patients with bipolar disorder. Am J Psychiatry. 2005;162:616-618.
53. Emamghoreishi M, Schlichter L, Li PP, et al. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry. 1997;154:976-982.
54. Dubovsky SL, Thomas M, Hijazi A, et al. Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci. 1994;243:229-234.
55. Yoon IS, Li PP, Siu KP, et al. Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder. Mol Psychiatry. 2001;6:678-683.
56. Kato T, Stine OC, McMahon FJ, et al. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. Biol Psychiatry. 1997;42:871-875.
57. Kato T, Kunugi H, Nanko S, et al. Mitochondrial DNA polymorphisms in bipolar disorder. J Affect Disord. 2001;62:151-164.
58. Kato T, Kunugi H, Nanko S, et al. Association of bipolar disorder with the 5178 polymorphism in mitochondrial DNA. Am J Med Genet. 2000;96:182-186.
59. Tanaka M, Gong J-S, Zhang J, et al. Mitochondrial genotype associated with longevity. Lancet. 1998;351:185-186.
60. Canter JA, Kallianpur AR, Parl FF, et al. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 2005;65:8028-8033.
61. Munakata K, Tanaka M, Mori K, et al. Mitochondrial DNA 3644T C mutation associated with bipolar disorder. Genomics. 2004;84:1041-1050.
62. Washizuka S, Iwamoto K, Kazuno AA, et al. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder in Japanese and the National Institute of Mental Health pedigrees. Biol Psychiatry. 2004;56:483-489.
63. Washizuka S, Kakiuchi C, Mori K, et al. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2003;120:72-78.
64. de Coo R, Buddiger P, Smeets H, et al. Molecular cloning and characterization of the active human mitochondrial NADH: ubiquinone oxidoreductase 24-kDa gene (NDUFV2) and its pseudogene. Genomics. 1995;26:461-466.
65. Detera-Wadleigh SD, Badner JA, Berrettini WH, et al. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci USA. 1999;96:5604-5609.
66. Esterling LE, Cox Matise T, Sanders AR, et al. An integrated physical map of 18p11.2: a susceptibility region for bipolar disorder. Mol Psychiatry. 1997;2:501-504.
67. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609-1623.
68. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300-308.
69. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005;14:241-253.
70. Cheng R, Juo SH, Loth JE, et al. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry. 2006;11:252-260.
71. Bezchlibnyk YB, Wang JF, McQueen GM, et al. Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J Neurochem. 2001;79:826-834.
72. Benes FM, Matzilevich D, Burke RE, et al. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry. 2006;11:241-251.
73. Kuloglu M, Ustundag B, Atmaca M, et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002;20:171-175.
74. Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121:109-122.
75. Ozcan ME, Gulec M, Ozerol E, et al. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004;19:89-95.
76. Frey BN, Andreazza AC, Kunz M, et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:283-285.
77. Wang JF, Azzam JE, Young LT. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience. 2003;116:485-489.
78. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry. 2005;58:879-884.
79. Lai JS, Zhao C, Warsh JJ, et al. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol. 2006;539:18-26.
80. King TD, Jope RS. Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport. 2005;16:597-601.
81. Cui J, Shao L, Young LT, et al. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience. 2007;144:1447-1453.
82. Schafer M, Goodenough S, Moosmann B, et al. Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res. 2004;1005:84-89.
83. Li N, Ragheb K, Lawler G, et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2003;278:8516-8525.
84. Wei Z, Bai O, Richardson JS, et al. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res. 2003;73:364-368.
85. Wang H, Xu H, Dyck LE, et al. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res. 2005;81:572-580.
86. Frey BN, Valvassori SS, Reus GZ, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci. 2006;31:326-332.
87. Wang JF, Shao L, Sun X, et al. Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons. J Neurochem. 2004;88(6):1477-1484.
88. Wang JF, Shao L, Cui J, et al. The effect of mood stabilizing drug lithium on expression and activity of glutathione s-transferase isoenzymes in primary cultured rat cerebral cortical cells. Free Radical Research. 2006;40:S159.
89. Sharma R, Yang Y, Sharma A, et al. Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxid Redox Signal. 2004;6:289-300.
90. Shukla GS. Mechanism of lithium action: in vivo and in vitro effects of alkali metals on brain superoxide dismutase. Pharmacol Biochem Behav. 1987;26:235-240.
91. de Vasconcellos AP, Nieto FB, Crema LM, et al. Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem Res. 2006;31:1141-1151.
92. Li XM, Chlan-Fourney J, Juorio AV, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res. 1999;56:72-75.
93. Reiter RJ, Acuna-Castroviejo D, Tan DX, et al. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 2001;939:200-215.
94. Djordjevic VB. Free radicals in cell biology. Int Rev Cytol. 2004;237:57-89.
95. Chen B, Wang JF, Young LT. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol Psychiatry. 2000;48:658-664.
96. Wang JF, Bown C, Young LT. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol. 1999;55:521-527.
97. Shao L, Sun X, Xu L, et al. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci. 2006;78:1317-1323.
98. Hiroi T, Wei H, Hough C, et al. Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J. 2005;5:102-111.
99. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001;26:504-510.
100. Yu Z, Luo H, Fu W, et al. The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: suppression of oxidative stress and stabilization of calcium homeostasis. Exp Neurol. 1999;155:302-314.
101. Nigam SK, Goldberg AL, Ho S, et al. A set of endoplasmic reticulum proteins possessing properties of molecular chaperones includes CA2+ binding proteins and member of the thioredoxin superfamily. J Biol Chem. 1994;269:1744-1749.
102. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 1999;274:6039-6042.
103. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 1999;72:879-882.
104. Dong GX, Singh DK, Dendle P, et al. Regional expression of Bcl-2 mRNA and mitochondrial cytochrome c release after experimental brain injury in the rat. Brain Res. 2001;903:45-52.
105. Kowaltowski AJ, Vercesi AE, Fiskum G. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides. Cell Death Differ. 2000;7:903-910.
106. Chen RW, Qin ZH, Ren M, et al. Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem. 2003;84:566-575.
107. Ghribi O, Prammonjago P, Herman MM, et al. Abeta(1-42)-induced JNK and ERK activation in rabbit hippocampus is differentially regulated by lithium but is not involved in the phosphorylation of tau. Brain Res Mol Brain Res. 2003;119:201-206.
108. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: nature most versatile biological signal? FEBS J. 2006;273:2813-2838.
109. Gao K, Calabrese JR. Newer treatment studies for bipolar depression. Bipolar Disord. 2005;7:13-23. Can J Psychiatry 2007;52:763-771